Johnson & Johnson (JNJ)

$155.75

-1.13

(-0.72%)▲

Market is closed - opens 7 PM, 02 Oct 2023
star icon

Johnson & Johnson is a healthcare company that produces and sells a variety of products, including medical devices, pharmaceuticals, and consumer healthcare goods.

Insights on Johnson & Johnson

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 23.70B → 25.53B (in $), with an average increase of 3.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -68.0M → 5.14B (in $), with an average increase of 101.3% per quarter

  • Vs PG

    In the last 1 year, Procter & Gamble Company, The has given 15.5% return, outperforming this stock by 20.2%

  • Vs PG

    In the last 3 years, Procter & Gamble Company, The has given 4.9% return, outperforming this stock by 0.3%

Performance

  • $155.36
    $156.87
    $155.75
    downward going graph

    0.25%

    Downside

    Day's Volatility :0.96%

    Upside

    0.71%

    downward going graph
  • $147.91
    $177.11
    $155.75
    downward going graph

    5.03%

    Downside

    52 Weeks Volatility :16.49%

    Upside

    12.06%

    downward going graph

Returns

PeriodJohnson & JohnsonSector (Health Care)Index (NASDAQ Composite)
3 Months
-5.9%
-3.0%
-2.6%
6 Months
1.51%
0.5%
2.0%
1 Year
-4.66%
6.3%
16.6%
3 Years
4.61%
22.1%
20.6%

Highlights

Market Capitalization
378.3B
Book Value
$28.92
Dividend Share
4.58
Dividend Yield
3.03%
Earnings Per Share (EPS)
4.93
PE Ratio
31.82
PEG Ratio
3.79
Wall Street Target Price
180.85
Profit Margin
13.35%
Operating Margin TTM
27.66%
Return On Assets TTM
9.15%
Return On Equity TTM
17.09%
Revenue TTM
97.8B
Revenue Per Share TTM
37.44
Quarterly Revenue Growth YOY
6.3%
Gross Profit TTM
64.0B
EBITDA
34.3B
Diluted Eps TTM
4.93
Quarterly Earnings Growth YOY
0.09
EPS Estimate Current Year
10.03
EPS Estimate Next Year
10.9
EPS Estimate Current Quarter
2.62
EPS Estimate Next Quarter
2.7

Analyst Recommendation

Hold
    44%Buy
    55%Hold
    0
    0%Sell
Based on 27 Wall street analysts offering stock ratings for Johnson & Johnson(by analysts ranked 0 to 5 stars)
Based on 27 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
15
15
15
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 16.12%

Current $155.75
Target $180.85

Company Financials

FY17Y/Y Change
Revenue
76.5B
↑ 6.34%
Net Income
1.3B
↓ 92.14%
Net Profit Margin
1.7%
↓ 21.31%
FY18Y/Y Change
Revenue
81.6B
↑ 6.71%
Net Income
15.3B
↑ 1076.69%
Net Profit Margin
18.75%
↑ 17.05%
FY19Y/Y Change
Revenue
82.1B
↑ 0.59%
Net Income
15.1B
↓ 1.16%
Net Profit Margin
18.42%
↓ 0.33%
FY20Y/Y Change
Revenue
82.6B
↑ 0.64%
Net Income
14.7B
↓ 2.68%
Net Profit Margin
17.82%
↓ 0.6%
FY21Y/Y Change
Revenue
93.8B
↑ 13.55%
Net Income
20.9B
↑ 41.89%
Net Profit Margin
22.26%
↑ 4.44%
FY22Y/Y Change
Revenue
94.9B
↑ 1.25%
Net Income
17.9B
↓ 14.07%
Net Profit Margin
18.9%
↓ 3.36%
Q1 FY22Q/Q Change
Revenue
23.4B
↓ 5.56%
Net Income
5.1B
↑ 8.72%
Net Profit Margin
21.98%
↑ 2.89%
Q2 FY22Q/Q Change
Revenue
24.0B
↑ 2.54%
Net Income
4.8B
↓ 6.51%
Net Profit Margin
20.04%
↓ 1.94%
Q3 FY22Q/Q Change
Revenue
23.8B
↓ 0.95%
Net Income
4.5B
↓ 7.4%
Net Profit Margin
18.74%
↓ 1.3%
Q4 FY22Q/Q Change
Revenue
23.7B
↓ 0.36%
Net Income
3.5B
↓ 21.04%
Net Profit Margin
14.85%
↓ 3.89%
Q1 FY23Q/Q Change
Revenue
24.7B
↑ 4.39%
Net Income
-68.0M
↓ 101.93%
Net Profit Margin
-0.27%
↓ 15.12%
Q2 FY23Q/Q Change
Revenue
25.5B
↑ 3.17%
Net Income
5.1B
↓ 7664.71%
Net Profit Margin
20.15%
↑ 20.42%
FY17Y/Y Change
Total Assets
157.3B
↑ 11.4%
Total Liabilities
97.1B
↑ 37.23%
FY18Y/Y Change
Total Assets
153.0B
↓ 2.76%
Total Liabilities
93.2B
↓ 4.06%
FY19Y/Y Change
Total Assets
157.7B
↑ 3.12%
Total Liabilities
98.3B
↑ 5.42%
FY20Y/Y Change
Total Assets
174.9B
↑ 10.88%
Total Liabilities
111.6B
↑ 13.6%
FY21Y/Y Change
Total Assets
182.0B
↑ 4.07%
Total Liabilities
108.0B
↓ 3.24%
FY22Y/Y Change
Total Assets
187.4B
↑ 2.94%
Total Liabilities
110.6B
↑ 2.39%
Q1 FY22Q/Q Change
Total Assets
178.4B
↓ 2.01%
Total Liabilities
103.6B
↓ 4.03%
Q2 FY22Q/Q Change
Total Assets
177.7B
↓ 0.35%
Total Liabilities
101.4B
↓ 2.2%
Q3 FY22Q/Q Change
Total Assets
175.1B
↓ 1.46%
Total Liabilities
100.5B
↓ 0.83%
Q4 FY22Q/Q Change
Total Assets
187.4B
↑ 7.0%
Total Liabilities
110.6B
↑ 10.0%
FY17Y/Y Change
Operating Cash Flow
21.1B
↑ 12.2%
Investing Cash Flow
-14.9B
↑ 212.29%
Financing Cash Flow
-7.7B
↓ 10.27%
FY18Y/Y Change
Operating Cash Flow
22.2B
↑ 5.44%
Investing Cash Flow
-3.2B
↓ 78.7%
Financing Cash Flow
-18.5B
↑ 141.24%
FY19Y/Y Change
Operating Cash Flow
23.4B
↑ 5.47%
Investing Cash Flow
-6.2B
↑ 95.58%
Financing Cash Flow
-18.0B
↓ 2.67%
FY20Y/Y Change
Operating Cash Flow
23.5B
↑ 0.51%
Investing Cash Flow
-20.8B
↑ 236.21%
Financing Cash Flow
-6.1B
↓ 66.03%
FY21Y/Y Change
Operating Cash Flow
23.4B
↓ 0.54%
Investing Cash Flow
-8.7B
↓ 58.3%
Financing Cash Flow
-14.0B
↑ 129.53%
Q1 FY22Q/Q Change
Operating Cash Flow
4.0B
↓ 30.58%
Investing Cash Flow
-3.6B
↓ 209.36%
Financing Cash Flow
-4.4B
↑ 27.62%
Q2 FY22Q/Q Change
Operating Cash Flow
5.6B
↑ 40.26%
Investing Cash Flow
-2.6B
↓ 27.38%
Financing Cash Flow
-2.3B
↓ 48.44%
Q3 FY22Q/Q Change
Operating Cash Flow
6.3B
↑ 12.6%
Investing Cash Flow
-1.7B
↓ 35.54%
Financing Cash Flow
-3.9B
↑ 73.6%
Q1 FY23Q/Q Change
Operating Cash Flow
3.3B
↓ 39.12%
Investing Cash Flow
3.3B
-
Financing Cash Flow
6.1B
↑ 261.06%
Q2 FY23Q/Q Change
Operating Cash Flow
7.4B
↑ 128.4%
Investing Cash Flow
-461.0M
↓ 113.91%
Financing Cash Flow
147.0M
↓ 97.61%

Technicals Summary

Sell

Neutral

Buy

Johnson & Johnson is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Johnson & Johnson
Johnson & Johnson
-4.87%
1.51%
-4.66%
4.61%
11.5%
Procter & Gamble Company, The
Procter & Gamble Company, The
-5.31%
-1.08%
15.53%
4.94%
74.33%
Pfizer Inc.
Pfizer Inc.
-7.6%
-17.86%
-24.2%
-9.62%
-25.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Johnson & Johnson
Johnson & Johnson
31.82
31.82
3.79
10.03
0.17
0.09
0.03
28.92
Procter & Gamble Company, The
Procter & Gamble Company, The
24.8
24.8
4.98
5.31
0.31
0.1
0.03
19.46
Pfizer Inc.
Pfizer Inc.
8.53
8.53
1.17
3.31
0.23
0.08
0.05
17.54
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Johnson & Johnson
Johnson & Johnson
Hold
$378.3B
11.5%
31.82
13.35%
Procter & Gamble Company, The
Procter & Gamble Company, The
Buy
$344.9B
74.33%
24.8
17.87%
Pfizer Inc.
Pfizer Inc.
Hold
$181.2B
-25.07%
8.53
27.55%

QnA on Johnson & Johnson

  • QuestionAsked on: 1 Aug, 2023

    Which of the following US pharmaceutical firm's have been facing heavy lawsuits related to cancer causing chemical substances in its products.

    QnA result : 2 Aug, 2023User Profile Icon1434 people participated in the quiz

    74.27% of INDmoney users answered correctly that A U.S. judge shot down the company's second attempt to resolve tens of thousands of lawsuits. The company was looking to shift all lawsuits related liability to a new company and place the new company into bankruptcy.

    Pulse of INDMoney Users

    Johnson & Johnson
    74.27%blue tick
    Pfizer
    18.55%
    Novartis
    7.18%

Institutional Holdings

  • Vanguard Group Inc

    10.28%

  • BlackRock Inc

    8.28%

  • State Street Corporation

    5.89%

  • Geode Capital Management, LLC

    2.06%

  • Morgan Stanley - Brokerage Accounts

    1.73%

  • JPMorgan Chase & Co

    1.32%

Corporate Announcements

  • Johnson & Johnson Dividends March,2023

    In the quarter ending March,2023. Johnson & Johnson has declared dividend of $1.13

    Read More

Company Information

Johnson & Johnson - a multinational corporation founded in America - mainly caters to medical and consumer goods. The company's headquarters are in New Jersey, United States. The company was incorporated in 1886 by James, Robert, and Edward Mead Johnson. Johnson & Johnson is one of the world's most valuable corporations. It has nearly 250 subsidiary companies operating across 60 countries. Its products are selling in over 175 countries. Some well-known consumer products of Johnson & Johnson are Band-Aids, baby products, Tylenol medications, and other products. In 2020, Johnson & Johnson generated annual revenue of $82.584 billion. Joaquin Duato serves as the Chairman and CEO for Johnson & Johnson, along with Paul Stoffels as Vice Chairman of the Executive Committee for the company with several other members. The company was ranked 36 on the Fortune 500 list of the top corporations in the United States by total revenue in 2021. Johnson & Johnson is publicly traded on New York Stock Exchange as JNJ as its stock symbol, under the DJIA, S&P 100, and S&P 500. Currently Johnson & Johnson has a market cap of $407.73 Billion. It has a P.E ratio of 31.23. The shares of Johnson & Johnson are trading at $155.75. .

Organization
Johnson & Johnson
Employees
152700
CEO
Mr. Alex Gorsky
Industry
Health Technology

Discover More

FAQs